
Ornella Belvedere

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10619886/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator. Science, 1999, 285, 260-263.	12.6	1,041
2	Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood, 2001, 97, 198-204.	1.4	525
3	Using next-generation sequencing for high resolution multiplex analysis of copy number variation from nanogram quantities of DNA from formalin-fixed paraffin-embedded specimens. Nucleic Acids Research, 2010, 38, e151-e151.	14.5	101
4	Low-Dose Computed Tomography Screening for Lung Cancer and Pleural Mesothelioma in an Asbestos-Exposed Population: Baseline Results of a Prospective, Nonrandomized Feasibility Trial—An Alpe-Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002). Oncologist, 2007, 12, 1215-1224.	3.7	82
5	Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Nonâ€&mall Cell Lung Cancer: A Review of the Literature. Oncologist, 2007, 12, 451-464.	3.7	65
6	Impact of low-dose computed tomography screening on lung cancer mortality among asbestos-exposed workers. International Journal of Epidemiology, 2018, 47, 1981-1991.	1.9	16
7	A computational index derived from whole-genome copy number analysis is a novel tool for prognosis in early stage lung squamous cell carcinoma. Genomics, 2012, 99, 18-24.	2.9	15
8	Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001). Lung Cancer, 2004, 46, 99-106.	2.0	11
9	Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. Lung Cancer, 2016, 100, 30-37.	2.0	3
10	From the podium to the patient: bringing the 2008 ASCO meeting to the clinic. Anti-Cancer Drugs, 2008, 19, 941-956.	1.4	0